Is GlaxoSmithKline Poised to Head Higher?

| + More Articles
  • Like on Facebook
  • Share on Google+
  • Share on LinkedIn

With shares of GlaxoSmithKline (NYSE:GSK) trading around $51, is GSK an OUTPERFORM, WAIT AND SEE, or STAY AWAY? Let’s analyze the stock with the relevant sections of our CHEAT SHEET investing framework:

T = Trends for a Stock’s Movement

GlaxoSmithKline is global healthcare group engaged in the discovery, development, manufacturing, and marketing of pharmaceutical products. These products are vaccines, over-the-counter medicines, and health-related consumer products. GlaxoSmithKline’s principal pharmaceutical products are medicines in these areas: respiratory, antivirals, central nervous system, cardiovascular and urogenital, metabolic, antibacterials, oncology and emesis, dermatology, rare diseases, immuno-inflammation, vaccines, and HIV.

GlaxoSmithKline, the UK drugmaker, will press ahead with its big bet on emerging markets, despite turmoil in its scandal-hit Chinese business and volatility in developing economies. Sir Andrew Witty, chief executive, admitted there could be some short-term challenges ahead after recent market turbulence from Argentina to Turkey. But he insisted GSK’s heavy investment in the developing world would still pay off as rising incomes and growing populations increase demand for healthcare. “We’re prepared to take the short-run ups and downs to stay committed for the long-run direction of travel,” Sir Andrew said.

More Articles About:

To contact the reporter on this story: staff.writers@wallstcheatsheet.com To contact the editor responsible for this story: editors@wallstcheatsheet.com

Yahoo Finance, Harvard Business Review, Market Watch, The Wall St. Journal, Financial Times, CNN Money, Fox Business